according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

SECTION 1. IDENTIFICATION

Product name : Sitagliptin / Metformin Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel

unwell. Rinse mouth.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 08/11/2025 27095-00025 Date of first issue: 10/31/2014 5.3

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
metformin hydrochlo- ride	No data availa- ble	1115-70-4	>= 60 - < 80 *
Sitagliptin Phosphate	No data availa- ble	654671-77-9	>= 5 - < 10 *
Cellulose	No data availa- ble	9004-34-6	>= 1 - < 5 *
Titanium dioxide	Titanic anhy- dride	13463-67-7	>= 0.1 - < 1 *

^{*} Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

Wash with water and soap. In case of skin contact

Get medical attention if symptoms occur.

If in eyes, rinse well with water. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting unless directed to do

> so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person. Contact with dust can cause mechanical irritation or drying of

Most important symptoms and effects, both acute and

the skin.

delayed

Dust contact with the eyes can lead to mechanical irritation.

Harmful if swallowed.

First Aid responders should pay attention to self-protection. Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Specific hazards during fire

fighting

 Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m3 (OEB 1)	Internal
Sitagliptin Phosphate	654671-77-9	TWA	0.6 mg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA (Respirable particulate matter)	2.5 mg/m³ (Titanium dioxide)	ACGIH

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection Material

: Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

Particulates type

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,380 mg/kg

Method: Calculation method

Components:

metformin hydrochloride:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,450 - 3,500 mg/kg

LD50 (Monkey): 463 mg/kg

LD50 (Rabbit): 350 mg/kg

LD50 (Guinea pig): 500 mg/kg

Sitagliptin Phosphate:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild skin irritation

Sitagliptin Phosphate:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild eye irritation

Sitagliptin Phosphate:

Species : Rabbit

Result : Irritating to eyes. Method : Draize Test

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Components:

Sitagliptin Phosphate:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species : Mouse Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Sitagliptin Phosphate:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Mouse Exposure time : 91 weeks

Dose : 1500 mg/kg body weight

Result : negative

Species : Rat, male
Application Route : Oral
Exposure time : 104 weeks

Dose : 900 mg/kg body weight

Result : negative

Species : Rat, female
Application Route : Oral
Exposure time : 104 weeks

LOAEL : 900 mg/kg body weight

Result : negative

Target Organs : Uterus (including cervix)

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Sitagliptin Phosphate:

Species : Mouse

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Application Route : Oral Exposure time : 2 Years Result : negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Titanium dioxide:

Species : Rat

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : positive

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

This substance(s) is not bioavailable and therefore does not

contribute to a dust inhalation hazard.

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in inhalation studies with

animals.

Reproductive toxicity

Not classified based on available information.

Components:

metformin hydrochloride:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 600 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 600 mg/kg body weight

Result: No teratogenic effects.

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight

Result: No teratogenic effects.

Sitagliptin Phosphate:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

metformin hydrochloride:

Species : Rat
NOAEL : 125 mg/kg
Application Route : Oral
Exposure time : 1 year

Remarks : No significant adverse effects were reported

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Species : Rabbit

NOAEL : 100 mg/kg

Application Route : Oral

Exposure time : 1 Year

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 50 mg/kg Application Route : Subcutaneous

Exposure time : 2 year

Remarks : No significant adverse effects were reported

Sitagliptin Phosphate:

Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg

Application Route : Oral
Exposure time : > 2 y
Target Organs : Kidney

Species : Rat
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Titanium dioxide:

Species : Rat

NOAEL : 24,000 mg/kg Application Route : Ingestion Exposure time : 28 Days

Species : Rat NOAEL : 10 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

metformin hydrochloride:

Skin contact : Remarks: May irritate skin. Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal dis-

comfort, flatulence, asthenia, Fatigue, Headache

Sitagliptin Phosphate:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhea

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

metformin hydrochloride:

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

plants

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 40 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Sitagliptin Phosphate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Persistence and degradability

Components:

metformin hydrochloride:

Biodegradability : Result: rapidly degradable

Biodegradation: 50 % Exposure time: 2 hrs

Sitagliptin Phosphate:

Biodegradability : Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)

Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

metformin hydrochloride:

Partition coefficient: n-

octanol/water

log Pow: -2

Sitagliptin Phosphate:

Partition coefficient: n-

octanol/water

log Pow: -0.03

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 08/11/2025 27095-00025 Date of first issue: 10/31/2014 5.3

Mobility in soil

Components:

metformin hydrochloride:

Distribution among environ-

: log Koc: 4.3

mental compartments Method: OECD Test Guideline 106

: log Koc: 4.37

Sitagliptin Phosphate:

Distribution among environ-

mental compartments

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS not determined

DSL not determined

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average CA AB OEL / TWA : 8-hour Occupational exposure limit CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: Nch - Chilean Norm: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

according to the Hazardous Products Regulations



Sitagliptin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 5.3 08/11/2025 27095-00025 Date of first issue: 10/31/2014

compile the Material Safety

eChem Portal search results and European Chemicals Agen-

Data Sheet cy, http://echa.europa.eu/

Revision Date : 08/11/2025 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8